Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients

Theodoraki, Marie‐Nicole; Yerneni, Saigopalakrishna S.; Hoffmann, Thomas; Gooding, William E.; Whiteside, Theresa L.

doi:10.1158/1078-0432.ccr-17-2664

Cited by 520 publications

(516 citation statements)

References 39 publications

Supporting

Mentioning

495

Contrasting

Unclassified

Order By: Relevance

“…C) The heatmap of Δ F norm values of HOLMES‐Exo PD‐L1 for PD‐L1 negative and positive exosomes at different concentrations of exosomes, and the PD‐L1 antibody for PD‐L1 positive exosomes at different concentrations of exosomes. D) Comparison of our method with previously reported methods (ELISA, FCM) indicates that our present method required less time and minimal reaction volume, and it did not require extra separation of unbound aptamers.…”

Section: Resultsmentioning

confidence: 64%

Homogeneous, Low‐volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD‐L1 for Cancer Diagnosis and Immunotherapy Response Prediction

et al. 2020

View full text Add to dashboard Cite

Immunotherapy has revolutionized cancer treatment, but its efficacy is severely hindered by the lack of effective predictors. Herein, we developed a homogeneous, low‐volume, efficient, and sensitive exosomal programmed death‐ligand 1 (PD‐L1, a type of transmembrane protein) quantitation method for cancer diagnosis and immunotherapy response prediction (HOLMES‐ExoPD‐L1). The method combines a newly evolved aptamer that efficiently binds to PD‐L1 with less hindrance by antigen glycosylation than antibody, and homogeneous thermophoresis with a rapid binding kinetic. As a result, HOLMES‐ExoPD‐L1 is higher in sensitivity, more rapid in reaction time, and easier to operate than existing enzyme‐linked immunosorbent assay (ELISA)‐based methods. As a consequence of an outstanding improvement of sensitivity, the level of circulating exosomal PD‐L1 detected by HOLMES‐ExoPD‐L1 can effectively distinguish cancer patients from healthy volunteers, and for the first time was found to correlate positively with the metastasis of adenocarcinoma. Overall, HOLMES‐ExoPD‐L1 brings a fresh approach to exosomal PD‐L1 quantitation, offering unprecedented potential for early cancer diagnosis and immunotherapy response prediction.

show abstract

Section: Resultsmentioning

confidence: 64%

Homogeneous, Low‐volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD‐L1 for Cancer Diagnosis and Immunotherapy Response Prediction

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Various other liquid biomarkers may provide additional diagnostic and prognostic information in HNSCC. Examples include elevated serum miR‐21, circulating PD‐L1 + exosomes, and presence of the TGFβ 1 genotype, all of which may be associated with a poorer prognosis.…”

Section: Biomarkers From Liquid Biopsiesmentioning

confidence: 99%

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy

Hsieh

Wang

et al. 2019

Head & Neck

View full text Add to dashboard Cite

Background Biomarkers in head and neck squamous cell carcinoma (HNSCC) emerge rapidly in recent years, especially for new targeted therapies and immunotherapies. Methods Recent, relevant peer‐reviewed evidence were critically reviewed and summarized. Results This review article briefly introduces essential biomarker concepts, including purposes and classifications (predictive, prognostic, and diagnostic markers), and the phases of biomarker development. We summarize current biomarkers in order of clinical utility; p16 and human papillomavirus status remain the most important and validated biomarkers in HNSCC. The rationale for biomarker study design continues to evolve with technological advances, especially whole‐exome or whole‐genomic sequencing. Noninvasive body fluid and liquid biopsy biomarkers appear to hold strong potential for development as tools for early cancer detection, cancer diagnosis, monitoring of disease recurrence, and outcome prediction. In light of discrepancies among different technologies, standardized approaches are needed. Conclusion Biomarkers from cancer tissue or blood in HNSCC could direct new anticancer therapies.

show abstract

“…In the context of tumor‐derived exosomes, the levels of exosomal programmed death‐ligand 1 (PD‐L1) have been intensively investigated. Studies have shown that levels of exosomal PD‐L1 are associated with tumor progression in different types of malignancies such as metastatic melanoma, glioblastoma, and head and neck and breast cancers . Among various potential mechanisms, Poggio et al .…”

Section: Introductionmentioning

confidence: 99%

Intercellular transfer of HLA‐G: its potential in cancer immunology

Lin

Yan

2019

Clin & Trans Imm

View full text Add to dashboard Cite

Intercellular protein transfer between cancer cells and immune cells is a very common phenomenon that can affect different stages of host antitumor immune responses. HLA‐G, a non‐classical HLA class I antigen, has been observed to be widely expressed in various malignancies, and its immune‐suppressive functions have been well recognised. HLA‐G expression in cancer cells can directly mediate immune tolerance by interacting with inhibitory receptors such as ILT2 and ILT4 expressed on immune cells. Moreover, a network of multiple directional intercellular transfers of HLA‐G among cancer cells and immune cells through trogocytosis, exosomes and tunnelling nanotubes provides malignant cells with an alternative ploy for antigen sharing and induces more complex heterogeneity, to modulate immune responses, ultimately leading to immune evasion, therapy resistance, disease progression and poor clinical outcome. Herein, we discuss the relative aspects of the intercellular transfer of HLA‐G between tumor cells and immune cells and its potential use in tumor immunology research and translational cancer therapy.

show abstract

Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients

Abstract: Circulating PD-L1 exosomes in HNC patients' plasma but not soluble PD-L1 levels associate with disease progression. .

Cited by 520 publications

References 39 publications

Homogeneous, Low‐volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD‐L1 for Cancer Diagnosis and Immunotherapy Response Prediction

Homogeneous, Low‐volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD‐L1 for Cancer Diagnosis and Immunotherapy Response Prediction

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy

Intercellular transfer of HLA‐G: its potential in cancer immunology

Contact Info

Product

Resources

About